Sun Pharma said to be planning upgrades, new R&D facility at troubled Madhya Pradesh facility


Sun Pharmaceutical, India’s largest generics maker, is reportedly looking to make a “significant investment” at the troubled facility in Madhya Pradesh the company inherited when it acquired Ranbaxy Laboratories for $4 billion.

The Dewas site in Madhya Pradesh is one of four manufacturing facilities that were banned by the FDA while they were operating under the Ranbaxy flag.

The improvements at the site by Sun are reported to include a new R&D facility, liveMint reported. Sun recently signed a deal with the Indian government to work towards eradicating malaria.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Sun officials have repeatedly said following the Ranbaxy buyout last year that as they integrate the two companies they would also upgrade the four Ranbaxy plants in India that made the FDA banned list for data integrity problems and other issues.

In May, Sun said that it would be looking for the FDA to reinspect at least one of the plants by the end of the year.

Suggested Articles

Novartis' AveXis will use Catalent for some manufacturing of its newly approved gene therapy Zolgensma and more manufacturing news of note.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps. 

Precision BioSciences says it will have a manufacturing facility for its off-the-shelf CAR-T therapies up and running in the fourth quarter.